News
A brain aneurysm (also called a cerebral aneurysm or an intracranial aneurysm) is a ballooning arising from a weakened area in the wall of a blood vessel in the brain. If the brain aneurysm expands ...
Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular ...
Intracerebral Hemorrhage (ICH) is the deadliest subtype of stroke, necessitating timely and accurate prognostic evaluation to reduce mortality and disability. However, the multifactorial nature and ...
Brain swelling, or cerebral edema, is a medical emergency. Learn about the evidence-based treatments doctors use to reduce ...
Ferroptosis, a form of regulatory non-apoptotic cell death driven by iron-dependent lipid peroxidation, accounts for more than 80% of the total types of neuronal death in the acute phase of ...
The CATALYST meta-analysis pooled the four studies and identified 5,441 people with acute ischemic stroke and Afib for ...
Neck pain Seizures These symptoms may look like other health problems. Get medical care right away if you have these symptoms. A brain aneurysm can lead to a subarachnoid hemorrhage. A brain aneurysm ...
Bollywood superstar Salman Khan recently disclosed his battle with serious health conditions, including trigeminal neuralgia, ...
Intensive BP-lowering initiated within several hours of intracerebral haemorrhage onset was safe and improved functional recovery, without a clear effect on haematoma growth. The greatest benefits for ...
Tubridge flow-diverting stent for treatment of unruptured intracranial complex aneurysms - Frontiers
To investigate the efficacy and safety of the Tubridge flow diverter (TFD) in treating unruptured intracranial complex aneurysms. Methods A retrospectively was performed on consecutive patients with ...
BACKGROUND: Red blood cell transfusions are commonly administered to anemic patients with spontaneous intracerebral hemorrhage (ICH); however, the optimal hemoglobin threshold to initiate transfusion ...
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results